(Q37866299)

24 August 2017

1 reference

title

Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy (English)

1 reference

24 August 2017

Baptist Gallwitz

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

18 April 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

723-732

1 reference

Therapeutic strategies based on glucagon-like peptide 1.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.576667

10.1517/13543784.2011.576667

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference